Investigation the effect of trehalose on PSP

Not Applicable

• Conditions: G23.1; PSP (progressive supranuclear palsy).; Progressive supranuclear ophthalmoplegia [Steele-Richardson-Olszewski]

• Registration Number: IRCT20181022041407N5
• Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 24 June 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 1

Inclusion Criteria

Patient with PSP diagnosis (according to NINDS-PSP criteria)
Satisfaction for participation in the research project

Exclusion Criteria

Uncontrolled and severe adverse event

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Patient`s Function. Timepoint: Baseline and after 3 months. Method of measurement: Using the PSP rating scale (PSP-RS).

Secondary Outcome Measures

Name	Time	Method
Interleukin-6 (IL-6). Timepoint: Baseline and after 3 months. Method of measurement: Blood test.;C-Reactive Protein (CRP). Timepoint: Baseline and after 3 months. Method of measurement: Blood test.;Neutrophil-to-lymphocyte ratio (NLR). Timepoint: Baseline and after 3 months. Method of measurement: Blood test.